Sintomas depressivos no câncer de mama: Inventário de Depressão de Beck - Short Form

Cangussu, Renata de Oliveira; Soares, Thiago Barbabela de Castro; Barra, Alexandre de Almeida; Nicolato, Rodrigo

doi:10.1590/s0047-20852010000200005

Cited by 18 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,[8][9][10]13,14 However, these studies refer not only to depression, but include all types of depressive disorders. Major depression should not be confused with a simple sense of sadness, with transient changes in mood or mild depressive symptoms -to do so risks overestimating its prevalence; it is critical to assess patients carefully for the presence of depressive symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…3 Cancer places specific demands on individuals, with substantial stressors both at diagnosis and during treatment. 4 Mammary neoplasms make demands on women's physical and psychological aspects, 5 and within the analysis of the patients' surgical and adjuvant treatment the impact on their mental health should be emphasized 6 .…”

Section: Introductionmentioning

confidence: 99%

“…These studies generally encompass all depressive disorders and not just major depression. 5,13,14 A lack of standardization, especially with regards to methods of assessment, questionnaire scores to measure depression and diagnostic criteria contribute to the large discrepancy between the values. In general, the more specifically the term 'depression' is defined and evaluated, the lower the prevalence rates reported, including a meta-analysis published in 2011 in The Lancet, in which the authors identified an association between low prevalence of depression and high-quality studies published recently.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of Major Depression in Patients With Breast Cancer

Carvalho

Bezerra

Freitas

et al. 2015

J. Hum. Growth Dev.

View full text Add to dashboard Cite

ABSTRACT:Introduction: breast cancer is one of the main causes of death among women in Brazil and worldwide. The diagnosis of breast neoplasms usually represents an emotional burden, and it may lead to adjustment reactions and even be the trigger for affective disorders (mainly depression), anxiety or psychosis. The Beck Depression Inventory (BDI) is one of the most used mechanisms for the evaluation of depression in research and in clinics. Depression prevalence in patients with cancer varies from 3% to 55% among different studies. Methodological variation, different instruments to assess depression and different cut-off points for diagnosis contribute to the huge discrepancy in current findings. In general, the more specifically depression is defined and evaluated, the lower the rates of prevalence are reported. Many articles fail to demonstrate a statistical significance in the relationship between depression and cancer-specific factors. This suggests that risk factors for depression in those patients are more related to the patient as contextual variables and premorbid factors of personality -and not to the cancer or its treatment. Objective: to determine the prevalence of major depression in women with breast cancer. Methods: a cross-sectional study was conducted in women with breast cancer. The sample consisted of 51 patients who answered the Beck Depression Inventory (BDI). The presence of depression was considered in cases where the scores were above 20. A questionnaire with additional data about the patients such as age, marital status, ethnicity, education, family income, family history of depression and breast cancer, and cancer-related variables including staging, months since diagnosis, treatment modality, type of surgery, alopecia occurring were used. Descriptive analysis and test of association (chi-square) were conducted. Results: the prevalence of major depression was 5.9%, similar to that observed in community samples. Subsyndromal depressive symptoms had a score of 21.6% (BDI scores from 16 to 20). Chi-square test was conducted and showed no statistically significant relationship between the classification of BDI and the variables tested (characteristics related to patient and cancer-specific). This indicates that the isolated context of the variables does not influence the event of depression. Conclusion: the prevalence of major depression in women with breast neoplasms was 5.9%.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Major Depression in Patients With Breast Cancer

Carvalho

Bezerra

Freitas

et al. 2015

J. Hum. Growth Dev.

View full text Add to dashboard Cite

show abstract

“…Thus, more researchers have been concerned about investigating the needs of survivors of breast cancer, aiming at a more global attention to the female group. (3) Recent models of definitions and concepts of Quality of Life related to health are being applied to cancer patients. Validated instruments are used to measure and explore effects and symptoms of the disease, as well as to evaluate the Quality of Life after treatment.…”

Section: Introductionmentioning

confidence: 99%

Qualidade de vida em mulheres com neoplasias de mama em quimioterapia

et al. 2014

View full text Add to dashboard Cite

Objective: This study aimed to assess the health-related quality of life of women with breast cancer undergoing chemotherapy. Methods: A cross-sectional study carried out in a specialized institution, comprising 145 women. Two standardized questionnaires for health-related quality translated and validated for the Portuguese language were used. The scores manual of the EORTC was used to calculate the domain scores of the questionnaires. Results: According to the first questionnaire, the emotional function was the most affected. The treatment causes financial difficulties for most patients (mean = 41.83). The symptoms with the highest scores were Insomnia (37.93), Fatigue (36.01) and Loss of Appetite (33.56). According to the Quality of Life Questionnaire − Breast Cancer 23, the mean score for Side effects was 50.07, meaning that many women experience side effects of chemotherapy, and impaired sexual satisfaction. Conclusion: Women with breast cancer showed changes in the following domains: financial, emotional, sexual satisfaction and future prospects. The most frequently mentioned symptoms were fatigue, insomnia and loss of appetite. ResumoObjetivo: Conhecer a qualidade de vida relacionada à saúde de mulheres com câncer de mama em tratamento quimioterápico. Métodos: Estudo transversal realizado em instituição especializada, não qual foram incluídas 145 mulheres. Foram utilizados dois questionários padronizados de qualidade relacionada à saúde, traduzidos e validados para a lingua portuguêsa. Utilizou-se o Manual dos Escores da EORTC para calcular os escores dos domínios dos questionários. Resultados: Segundo o primeiro questionário, a função mais afetada foi a emocional. O tratamento provoca dificuldade financeira na maioria das pacientes (média = 41,83). Os sintomas com os maiores escores foram Insônia (37,93), Fadiga (36,01) e Perda de apetite (33,56). Segundo o instrumento Quality of Life Questionnaire − Breast Cancer 23, o escore Efeitos Colaterais teve média de 50,07, significando que muitas mulheres apresentam efeitos colaterais da quimioterapia e satisfação sexual prejudicada. Conclusão: Mulheres com câncer de mama apresentaram alterações nos domínios emocional, financeiro, de satisfação sexual e nas perspectivas futuras. Os sintomas mais mencionados foram fadiga, insônia e perda de apetite.

show abstract

“…According to Cangussu et al 19 , depressive symptoms are revealed more frequently in the presence of pain and limitation of movement in the superior member. Moskowitz 20 relates that the survivors of breast cancer re-join work with lines of anxiety and/or depression, signs of physical tiredness and cognitive limitations on labor activities.…”

Section: Discussionmentioning

confidence: 99%